We are Napo Therapeutics: an European pharmaceutical company, a young start-up led by a team of experienced professionals. Our mission is to improve the quality of life of people suffering from rare diseases and pathologies with a strong unmet medical need through innovative solutions. Our name reflects our story: The Napo River crosses the territories of the Amazon where the Croton lechleri tree grows – the plant from which we extract the sap that contains a precious active ingredient. We are investigating an innovative and first-in-class drug thanks to the novel mechanism of action of this active ingredient, in order to register it throughout Europe. Right now, our focus is on two serious rare diseases: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD). Napo Therapeutics is a European Company headquartered in Milan. Our majority shareholder is Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health, which is headquartered in San Francisco, California and listed on NASDAQ (JAGX).
Location: Italy, Lombardy, Milan
Employees: 11-50
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | SPRIM Glob... | sprim.net |
Mentions in press and media 3
| Date | Title | Description |
| 19.11.2024 | Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year – Europe” | Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar’s novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN FRANCISCO, CA / ACCESSWIRE / November 19, ... |
| 09.02.2023 | Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A. | This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million Jaguar currently owns approximately 73.5% of Napo Therape... |
| 31.03.2022 | Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets | Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human indications of crofelemer approved in the ... |